Opinion|Videos|January 22, 2024
The Impact of Biomarkers in Clinical Decision-Making and Emergent Agents in HR+/HER2- Metastatic Breast Cancer
Author(s)Virginia G. Kaklamani, MD
Virginia Kaklamani, MD, DSc, explains that in second-line treatment of metastatic HR+/HER2- breast cancer after CDK4/6 inhibitors, biomarker testing guides the choice between therapies based on the safety and resistance mutation profiles.
Advertisement
Episodes in this series
Advertisement
Related to this article
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5